<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="408">
  <stage>Registered</stage>
  <submitdate>4/11/2003</submitdate>
  <approvaldate>4/11/2003</approvaldate>
  <nctid>NCT00072293</nctid>
  <trial_identification>
    <studytitle>Surgical Resection With or Without Axillary Lymph Node Dissection in Treating Women With Node-Negative Breast Cancer and Sentinel Lymph Node Micrometastases</studytitle>
    <scientifictitle>A Randomized Trial Of Axillary Dissection Versus No Axillary Dissection For Patients With Clinically Node Negative Breast Cancer And Micrometastases In The Sentinel Node</scientifictitle>
    <utrn />
    <trialacronym>23-01</trialacronym>
    <secondaryid>IBCSG 23-01</secondaryid>
    <secondaryid>CDR0000339581</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Breast Cancer</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Breast</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Other cancer types</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: surgery - Axillary lymph node dissection
Treatment: surgery - No axillary lymph node dissection

Active Comparator: Axillary Dissection - Patients undergo surgical resection of the primary tumor with axillary lymph node dissection following sentinel lymph node assessment.

Experimental: No Axillary Dissection - Patients undergo surgical resection of the primary tumor with no axillary lymph node dissection following sentinel lymph node assessment.


Treatment: surgery: Axillary lymph node dissection
Axillary lymph node dissection

Treatment: surgery: No axillary lymph node dissection
Therapeutic conventional surgery

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: surgery</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>5-year Disease-Free Survival - Estimated percentage of patients alive and disease-free at 5 years from randomization, where disease-free survival is defined as the time from randomization to first evidence of invasive relapse at any site, second primary tumor (contralateral or non-breast) or death.</outcome>
      <timepoint>5-year estimate reported after a median follow-up of 60 months</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>5-year Overall Survival - Estimated percentage of patients alive and disease-free at 5 years from randomization, where overall survival is defined as the time from randomization to death of any cause.</outcome>
      <timepoint>5-year estimate reported after a median follow-up of 60 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Site of Recurrence - Site of recurrence of breast cancer</outcome>
      <timepoint>Reported after a median follow-up of 60 months</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>DISEASE CHARACTERISTICS:

          -  Clinical, mammographic, ultrasonographic, or pathologic diagnosis of unicentric and
             unifocal breast carcinoma

          -  Largest tumor lesion = 5 cm

          -  Palpable or nonpalpable breast lesion

               -  Preoperative radioactive occult lesion localization, hook wire, or other method
                  of localization required for nonpalpable lesions

          -  Prior (preoperative) or planned (intraoperative) sentinel node biopsy required

               -  At least 1 micrometastatic (i.e., no greater than 2 mm) sentinel lymph node with
                  no extracapsular extension

          -  No clinical evidence of distant metastases

               -  No suspicious manifestation of metastases that cannot be ruled out by x-ray, MRI,
                  or CT scan, including the following:

                    -  Skeletal pain of unknown cause

                    -  Elevated alkaline phosphatase

                    -  Bone scan showing hot spots

          -  No palpable axillary lymph node(s)

          -  No Paget's disease without invasive cancer

          -  Hormone receptor status:

               -  Estrogen receptor and progesterone receptor known

        PATIENT CHARACTERISTICS:

        Age

          -  Any age

        Sex

          -  Female

        Menopausal status

          -  Any status

        Performance status

          -  Not specified

        Life expectancy

          -  Not specified

        Hematopoietic

          -  Not specified

        Hepatic

          -  See Disease Characteristics

        Renal

          -  Not specified

        Other

          -  Not pregnant or nursing

          -  No other prior or concurrent malignancy except the following:

               -  Adequately treated basal cell or squamous cell skin cancer

               -  Adequately treated carcinoma in situ of the cervix

               -  Adequately treated in situ melanoma

               -  Contralateral or ipsilateral carcinoma in situ of the breast

          -  No psychiatric, addictive, or other disorder that may compromise ability to give
             informed consent

          -  Geographically accessible for follow-up

        PRIOR CONCURRENT THERAPY:

        Biologic therapy

          -  Not specified

        Chemotherapy

          -  Not specified

        Endocrine therapy

          -  Not specified

        Radiotherapy

          -  Not specified

        Surgery

          -  See Disease Characteristics

        Other

          -  No prior systemic therapy for breast cancer

          -  More than 1 year since prior chemopreventive agent</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Female</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria />
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate />
    <actualstartdate>1/12/2001</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>931</actualsamplesize>
    <recruitmentstatus>Active, not recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>1/12/2021</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW,SA,VIC,WA</recruitmentstate>
    <hospital>Lismore Base Hospital - Lismore</hospital>
    <hospital>St Vincents Hospital - Lismore</hospital>
    <hospital>Mater Hospital - North Sydney - North Sydney</hospital>
    <hospital>Royal North Shore Hospital - St. Leonards</hospital>
    <hospital>Sydney Cancer Centre at Royal Prince Alfred Hospital - Sydney</hospital>
    <hospital>Riverina Cancer Care Centre - Wagga Wagga</hospital>
    <hospital>Westmead Institute for Cancer Research at Westmead Hospital - Westmead</hospital>
    <hospital>Royal Adelaide Hospital Cancer Centre - Adelaide</hospital>
    <hospital>Royal Melbourne Hospital - Parkville</hospital>
    <hospital>St. John of God Hospital - Bunbury - Bunbury</hospital>
    <postcode>2480 - Lismore</postcode>
    <postcode>2060 - North Sydney</postcode>
    <postcode>2065 - St. Leonards</postcode>
    <postcode>2050 - Sydney</postcode>
    <postcode>2650 - Wagga Wagga</postcode>
    <postcode>2145 - Westmead</postcode>
    <postcode>5000 - Adelaide</postcode>
    <postcode>3050 - Parkville</postcode>
    <postcode>6230 - Bunbury</postcode>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Liege</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Brazil</country>
      <state>Rio Grande do Sul</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Denmark</country>
      <state>Horsholm</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Villejuif</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Aviano</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Bergamo</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Bologna</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Ferrara</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Lecco</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Milan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Pavia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Auckland</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Hamilton</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Peru</country>
      <state>Lima</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Slovenia</country>
      <state>Ljubljana</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Switzerland</country>
      <state>Aarau</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Switzerland</country>
      <state>Bellinzona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Switzerland</country>
      <state>Bern</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Switzerland</country>
      <state>Lausanne</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Switzerland</country>
      <state>St. Gallen</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Other</primarysponsortype>
    <primarysponsorname>International Breast Cancer Study Group</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>RATIONALE: Surgery to remove lymph nodes in the armpit in patients with sentinel lymph node
      micrometastases may remove cancer cells that have spread from tumors in the breast. It is not
      yet known whether surgery to remove the primary tumor is more effective with or without
      axillary lymph node dissection.

      PURPOSE: This randomized phase III trial is studying surgery and axillary lymph node
      dissection to see how well they work compared to surgery alone in treating women with
      node-negative breast cancer and sentinel lymph node micrometastases.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00072293</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Viviana E. Galimberti</name>
      <address>European Institute of Oncology</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>